#USA #Cancer Research #Plymouth Meeting #NCCN #Nancy Lewis

Dr. Nancy L. Lewis Appointed as Chief Scientific Officer at NCCN

On April 9, 2026, the National Comprehensive Cancer Network® (NCCN®), a prominent alliance of leading cancer centers, announced the appointment of Dr. Nancy L. Lewis, MD, MBS, FACP, as the new Chief Scientific Officer (CSO). This pivotal role will see Dr. Lewis overseeing NCCN's clinical trial programs while aiming to elevate patient care standards, research, and education in oncology.

Dr. Lewis brings extensive expertise in medical research, particularly in clinical trials for solid tumors and hematologic malignancies. Prior to joining NCCN, she served as Senior Director of Clinical Programs at Novartis Pharmaceuticals and was an Associate Professor at various prestigious academic cancer centers. Dr. Lewis holds degrees from Pennsylvania State University, Temple University School of Medicine, and Rutgers University, along with completing her residency at the University of Rochester and fellowship at the Fox Chase Cancer Center, a founding institution of NCCN.

Crystal S. Denlinger, MD, CEO of NCCN, expressed enthusiasm about Dr. Lewis's appointment: “This is a crucial time for cancer research; we have many advancements to capitalize on, but much work lies ahead. Dr. Lewis is the right person to oversee our efforts in innovation and discovery that will enhance the lives of those with cancer.” She emphasized that Dr. Lewis will be a tremendous asset to the executive team, ensuring that NCCN’s research and clinical programs continue to drive oncology outcomes globally.

Previously, Dr. Lewis has been recognized by several esteemed cancer organizations, including the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Cancer Society (ACS). As CSO, she will collaborate closely on NCCN’s Oncology Research Program (ORP) and key elements of the NCCN Guidelines®, which are recognized as a standard for clinical guidance and policies in cancer treatment.

Additionally, Dr. Lewis will supervise the NCCN Biomarkers Compendium®, NCCN Radiation Therapy Compendium™, and NCCN Imaging Appropriate Use Criteria™. Beyond this, she will engage with the NCCN’s Continuing Medical Education program and participate in relevant global initiatives and policies.

“I am thrilled to join the National Comprehensive Cancer Network and contribute to its extraordinary legacy in advancing high-quality cancer care,” Dr. Lewis remarked. “I look forward to working with the exceptional collaborators at NCCN to address emerging challenges and drive innovative solutions that improve the lives of patients worldwide.”

Dr. Lewis will take over leadership from Dr. Denlinger, who previously held the CSO role before becoming CEO of the organization. She is set to assume her new responsibilities in May 2026.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®) is a non-profit alliance of leading cancer centers dedicated to patient care, research, and education in oncology. NCCN works to define and promote evidence-based practices in cancer prevention, treatment, and support services to ensure that all individuals are empowered to live healthier lives. The NCCN Guidelines® provide expert consensus recommendations for cancer care, making them the most comprehensive and updated resource available in the medical field. The NCCN Guidelines for Patients® offer valuable information to patients and caregivers, supported by the NCCN Foundation®. Visit NCCN.org for more information.